University of Groningen

Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma

Antonescu, Cristina R; Dickson, Brendan C; Sung, Yun-Shao; Zhang, Lei; Suurmeijer, Albert J H; Stenzinger, Albrecht; Mechttersheimer, Gunhild; Fletcher, Christopher D M

Published in:
American Journal of Surgical Pathology

DOI:
[10.1097/PAS.0000000000001575](https://doi.org/10.1097/PAS.0000000000001575)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Antonescu, C. R., Dickson, B. C., Sung, Y-S., Zhang, L., Suurmeijer, A. J. H., Stenzinger, A., Mechttersheimer, G., & Fletcher, C. D. M. (2020). Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma. *American Journal of Surgical Pathology*, 44(12), 1677-1684. <https://doi.org/10.1097/PAS.0000000000001575>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Recurrent *YAP1* and *MAML2* Gene Rearrangements in Retiform and Composite Hemangioendothelioma

Cristina R. Antonescu, MD,* Brendan C. Dickson, MD,† Yun-Shao Sung, MSc,* Lei Zhang, MD,* Albert J.H. Suurmeijer, MD,‡ Albrecht Stenzinger, MD,§ Gunhild Mechttersheimer, MD,§ and Christopher D.M. Fletcher, MD||

Abstract: Retiform and composite hemangioendotheliomas (CHEs) are both locally aggressive, rarely metastasizing vascular neoplasms characterized by arborizing vascular channels lined by endothelial cells with a hobnail morphology. CHE displays additional cytologic and architectural components, including often vacuolated epithelioid cells, solid areas, or features reminiscent of well-differentiated angiosarcoma. Triggered by an index case of a soft tissue retiform hemangioendothelioma (RHE) which revealed a *YAP1-MAML2* gene fusion by targeted RNA sequencing, we sought to investigate additional cases in this morphologic spectrum for this genetic abnormality. A total of 24 cases, 13 RHE and 11 CHE involving skin and soft tissue were tested by fluorescence in situ hybridization using custom BAC probes for rearrangements involving these genes. An additional visceral CHE with neuroendocrine differentiation was tested by targeted RNA sequencing. Among the soft tissue cohort, 5/13 (38%) RHE and 3/11 (27%) CHE showed *YAP1* gene rearrangements, with 5 cases showing a *YAP1-MAML2* fusion, including all 3 CHE. The single neuroendocrine CHE showed the presence of a *PTBPI-MAML2* fusion. All *YAP1*-positive CHE lesions occurred in female children at acral sites, compared with fusion-negative cases which occurred in adults, with a wide anatomic distribution. *YAP1*-positive RHE occurred preferentially in males and lower limb, compared with negative cases. These results suggest that RHE and CHE represent a morphologic continuum, sharing abnormalities in *YAP1* and *MAML2* genes. In contrast, the neuroendocrine CHE occurring in a 37-year-old male harbored a distinct *PTBPI-MAML2* fusion and showed aggressive clinical behavior (pancreatic mass with multiple liver and lung metastases).

These preliminary findings raise the possibility that neuroendocrine CHE may be genetically distinct from the conventional RHE/CHE spectrum. Further studies are needed to investigate the pathogenetic relationship of fusion-negative cases with this subset and, less likely, with other members of the HE family of tumors.

Key Words: composite hemangioendothelioma, retiform hemangioendothelioma, fusion, *YAP1*, *MAML2*

(*Am J Surg Pathol* 2020;00:000–000)

Retiform hemangioendothelioma (RHE) is a locally aggressive, rarely metastasizing, vascular lesion, characterized by distinctive arborizing blood vessels lined by endothelial cells with characteristic hobnail morphology, reminiscent of the normal rete testis. The lesions occur preferentially in the skin and subcutaneous tissue of the distal extremities, particularly in the lower limb.¹ Similar to RHE, classic composite hemangioendothelioma (CHE) is also classified as a locally aggressive, rarely metastasizing, vascular neoplasm. CHE is characterized by an admixture of histologically distinct components, with RHE being the most common architectural pattern, followed by epithelioid cell change, which may simulate epithelioid hemangioendothelioma (EHE).² Most CHE cases occur in young adults, with a slight female predominance, often involving distal extremities, especially the hands and feet, or the head and neck. An aggressive form of CHE showing neuroendocrine marker expression has also been described, associated with metastatic disease in more than half of the cases.³ No recurrent genetic abnormalities have been reported to date in either RHE or CHE, although *PTBPI-MAML2* and *EPC1-PCH2* gene fusions have been identified in single cases of neuroendocrine CHE.³ In this study, prompted by an index case of RHE with a *YAP1-MAML2* gene fusion, we have investigated a group of RHE and CHE for this genetic abnormality, to assess their pathogenetic relationship.

MATERIALS AND METHODS

Clinical data, including age, sex, and anatomic site were retrieved from pathology reports. Hematoxylin and eosin-stained slides from biopsy and resection specimens were rereviewed by 2 of us (C.R.A., C.D.M.F.). Pathologic features were recorded, including the type of vasof ormation (ie, retiform vascular channels, hemangioma-like), degree of

From the *Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; †Department of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada; ‡Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; §Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; and ||Department of Pathology, Brigham and Women's Hospital, Boston, MA.

Conflicts of Interest and Source of Funding: Supported in part by P50 CA 140146-01 (C.R.A.), P50 CA217694 (C.R.A.), P30 CA008748, Cycle for Survival (C.R.A.), Kristin Ann Carr Foundation (C.R.A.), EHE Foundation. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Correspondence: Cristina R. Antonescu, MD, Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 (e-mail: antonesc@mskcc.org).

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

cellularity, cytomorphology, nuclear pleomorphism, mitotic activity, type of stromal component, amount of inflammatory infiltrate, etc. In all cases, IHC for endothelial markers (CD31, ERG) were confirmed positive, and in a subset of cases, immunostaining for podoplanin (D2-40) and synaptophysin was also performed. As most of the cases originated from personal consultations, the limited material available was prioritized for molecular studies. A diagnosis of RHE was based on the presence of the characteristic elongated and narrow arborizing vascular channels, lined by monomorphic endothelial cells with protuberant nuclei, showing a typical tombstone or hobnail appearance, reminiscent of the normal rete testis. The cells showed scant cytoplasm and lack nuclear pleomorphism or increased mitotic activity, often blending with the underlying fibrotic stroma. Other architectural components were not present. In contrast, CHE was defined by at least 2 morphologically distinct vascular tumor elements, most often closely resembling RHE and EHE. Other less common patterns include hemangioma-like or areas resembling low-grade angiosarcomas. Similar to RHE, the degree of cytologic atypia was mild, with no increased mitotic activity or necrosis present. The study was approved by the Institutional Review Board.

Fluorescence In Situ Hybridization

Subsequent to the results obtained from targeted RNA sequencing in the index case, all tumors were tested by fluorescence in situ hybridization (FISH) for *YAP1* and *MAML2* gene rearrangements. Custom probes made by bacterial artificial chromosomes (BAC) clones flanking the *YAP1* and *MAML2* genes of interest according to the UCSC genome browser (<http://genome.ucsc.edu>) and obtained from BACPAC sources of Children's Hospital of Oakland Research Institute (Oakland, CA; <https://bacpacresources.org/>). DNA from each BAC was isolated according to the manufacturer's instructions. The BAC clones were labeled with fluorochromes (fluorescent-labeled dUTPs; Enzo Life Sciences, New York, NY) by nick translation and validated on normal metaphase chromosomes. The 4- μ m-thick formalin-fixed paraffin-embedded (FFPE) slides were deparaffinized, pretreated, and hybridized with denatured probes. After overnight incubation, the slides were washed, stained with 4',6-diamidino-2-phenylindole, mounted with an antifade solution, and then examined on a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany) controlled by Isis 5 software (Metasystems). Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan), controlled by Isis 5 software (Metasystems, Newton, MA). A positive score was interpreted when at least 20% of the nuclei showed a break-apart signal. Nuclei with an incomplete set of signals were omitted from the score.

Targeted RNA Sequencing

Two cases were analyzed by targeted RNA sequencing, using RNA extracted from FFPE tissue (cases 1 and 9). In the index case 1, the RNA was extracted with the Amsbio's ExpressArt FFPE Clear RNA Ready kit (Amsbio LLC, Cambridge, MA) and the fragment length was assessed with an RNA 6000 chip on an Agilent Bioanalyzer

(Agilent Technologies, Santa Clara, CA). RNA-sequencing libraries were prepared using 20 to 100 ng total RNA with the TruSight RNA Fusion Panel (Illumina, San Diego, CA). Targeted RNA sequencing was performed on an Illumina MiSeq platform. For case 9, RNA extracted by the automated Maxwell 16 Research extraction system (Promega, Madison, WI) was analyzed on an Ion Torrent S5 sequencing platform using the Archer FusionPlex Sarcoma Assay.⁴ Reads were independently aligned with STAR (version 2.3) against the human reference genome (hg19) and analyzed by STAR-Fusion.

RESULTS

Clinical and Pathologic Findings

Twenty-four cases of soft tissue hemangioendotheliomas from the authors consultation files were included in the study, subclassified as 13 RHE and 11 CHE, using well-defined World Health Organization (WHO) criteria and as described above.¹ The patients in both histologic groups had a wide age range at diagnosis, with 10 to 55 years (mean: 29 y) for the RHE group and 7 to 68 years (mean: 29 y) for the CHE group. The anatomic distribution was also variable, with both RHE and CHE lesions occurring in the skin or superficial soft tissues of the lower or upper extremity, and less frequently in the head and neck. An additional patient with a CHE with neuroendocrine features was included in the analysis. This patient was a 37-year-old male, who presented with a pancreatic mass and multiple liver and lung lesions consistent with metastases. Regardless of histologic subtype, the lesions were ill-defined and showed infiltrative growth, often associated with a densely fibrotic stroma, and patchy lymphocytic infiltrates. None of the cases showed evidence of nuclear pleomorphism, increased mitotic activity, or necrosis.

YAP1 Gene Rearrangements Are Detected in One Third of RHE

Among the 13 cases, 5 (38%) RHE showed the presence of *YAP1* gene rearrangements. The index case (case 1) of a 10-year-old with a superficial soft tissue mass on the knee (Fig. 1) was investigated by targeted RNA sequencing and showed an intrachromosomal inversion on 11q21-q22, resulting in a *YAP1-MAML2* fusion, with *YAP1* exon 5 fused to *MAML2* exon 2 (Fig. 2). An additional case (case 3) showed *MAML2* gene rearrangement by FISH, in addition to *YAP1* break-apart, while in the other 3 cases there were no abnormalities of *MAML2* gene detected.

There was no significant age difference between the *YAP1*-positive versus *YAP1*-negative molecular groups of RHE, with a mean age of 25 years (range: 10 to 50 y) versus a mean age of 33 years (range: 14 to 55 y), respectively. However, all except 1 patient with a *YAP1*-positive RHE occurred in males on the lower extremity, while in the molecular-negative group the sex and anatomic site distribution was variable (Tables 1, 2).

Morphologically, no differences were noted between the 2 molecular groups (Figs. 1, 4), or between tumors with

FIGURE 1. Morphologic features of RHE with *YAP1* gene rearrangements. A–F, Index case of a superficial soft tissue lesion from the knee in a 10-year-old male (case 1). Low-power view showing a vague nodular and infiltrating growth pattern within subcutis which appears heavily fibrotic (A). Medium power shows densely sclerotic stromal background with either elongated, staghorn vessels (B), or shorter, retiform vascular network, lined by small endothelial cells with scant cytoplasm (C), with patchy prominent lymphocytic infiltrate, obscuring the vascular proliferation (D). Tumor cells typically coexpress CD31 (E) and podoplanin (D2-40) (F). G and H, Cutaneous example showing elongated vascular channels infiltrating through the superficial dermis, lined by hobnailed endothelial cells (case 4, 10/male, buttock). I, Another RHE skin lesion in an adult (50/female, knee) showing angulated vessels with dilated lumina and protruding endothelial cells, some appearing detached and reminiscent of micropapillae. The vascular channels are embedded in stroma with abundant lymphocytic infiltrate (case 5).

YAP1-MAML2 fusions versus *YAP1* gene abnormalities alone. Microscopically, RHE were composed of variably sized, angulated blood vessels, with either widely open lumina or more, collapsed, narrow channels (Fig. 1). There was no discernible lobular growth pattern, instead, the vascular proliferation showed infiltrative growth, often extending to the inked margins. Most vascular lumens appeared empty, with only rare red blood cells. The endothelial lining typically displayed scant cytoplasm, with protruding, enlarged hobnailed nuclei. In some cases, the endothelial cells showed a moderate amount of eosinophilic cytoplasm, but vacuolated cells were relatively few (Fig. 1). Mitotic figures (MFs) were difficult to find (0 to 1 MFs/10 HPFs). Nuclear pleomorphism and necrosis were absent in all cases. One case showed intraluminal detached endothelial cells, reminiscent of micropapillary endothelial hyperplasia, however, none

showed the fibrous cores, typically seen in papillary intralymphatic angioendothelioma (Dabska tumor) (Fig. 1). All cases were associated with a densely fibrotic stroma, infiltrating, and encasing adipose tissue, as well as patchy lymphocytic infiltrates, in areas obscuring the vascular proliferation (Fig. 1).

In the index case, harboring *YAP1-MAML2* fusion, the material was available for further immunostaining, which showed positivity for podoplanin (D2-40), in addition to CD31 and ERG, while synaptophysin was negative (Fig. 1).

***YAP1-MAML2* Fusion-positive CHE Occur With Predilection for Female Children at Acral Sites**

Among the 11 cases, 3 (27%) CHE showed the presence of *YAP1* and *MAML2* gene rearrangements, in keeping with a *YAP1-MAML2* fusion. There was a significant

FIGURE 2. Diagrammatic representation of the *YAP1-MAML2* and *PTBP1-MAML2* fusions. A, Chromosomal location of *YAP1* gene locus in 11q22.1-q22.2, *PTBP1* in 19p13.3, and *MAML2* in 11q21; red vertical lines depict the genomic breakpoint locus. Arrows show the direction of transcription of each gene. B, Upper panel depicts the *YAP1-MAML2* transcript, composed of the first 5 exons of *YAP1* fused to most of *MAML2* (exons 2 to 5). The middle and lower panels show the 2 transcript isoforms of *PTBP1-MAML2*, composed of either the first 2 exons or the first 10 exons of *PTBP1* gene fused to *MAML2* gene exons 2 to 5. The protein domains of each of the genes involved are also schematically depicted.

difference in age at presentation in the molecular positive group, with a mean age of 8 years (range: 7 to 9 y), compared with the negative cases, where the mean age was 34 years (range: 12 to 68 y) (Table 1). Moreover, all *YAP1-MAML2* fusion-positive lesions occurred in females at acral sites, while the 8 negative cases had relatively even sex and wide anatomic distribution, with only 1 case occurring in a distal extremity (heel) (Tables 1, 2). Microscopically, the 3 fusion-positive CHE were characterized by variable amounts of RHE and epithelioid components. No other components were noted. The epithelioid cells were arranged in single cells, cords, solid nests, or ill-formed vascular channels, reminiscent of EHE. Intracytoplasmic vacuoles were noted in all cases. However, all lesions were associated with a densely fibrotic stroma, lacking the myxochondroid matrix typically seen in EHE. The RHE component ranged from predominant to very focal (Fig. 3), the angulated or elongated channels being lined by relatively small endothelial cells with hobnailed, uniformly hyperchromatic nuclei. All tumors showed low mitotic activity (0 to 1 MFs/10 HPFs), lacking nuclear pleomorphism or necrosis. In 1 case (case 8), the material

was available for further immunostaining, showing podoplanin (D2-40) reactivity (Fig. 3), while synaptophysin was negative.

TABLE 1. Clinicopathologic Features of RHE and CHE Cases Positive for *YAP1* and *MAML2* Gene Rearrangements

HE #	HE Type	Age/Sex	Site	Genetic Abnormality
1	RHE	10/male	Knee	<i>YAP1-MAML2</i> *†
2	RHE	31/male	Shoulder	<i>YAP1</i> †
3	RHE	23/male	Fourth toe	<i>YAP1-MAML2</i> †
4	RHE	10/male	Buttock	<i>YAP1</i> †
5	RHE	50/female	Knee	<i>YAP1</i> †
6	CHE	9/female	Foot	<i>YAP1-MAML2</i> †
7	CHE	9/female	Heel	<i>YAP1-MAML2</i> †
8	CHE	7/female	Middle finger	<i>YAP1-MAML2</i> †
9	NE-CHE	37/male	Pancreas, liver, and lung lesions	<i>PTBP1-MAML2</i> *

*Targeted RNA sequencing.
†FISH.
HE indicates hemangioendothelioma; NE-CHE, neuroendocrine composite hemangioendothelioma.

TABLE 2. Clinicopathologic Features of RHE and CHE Cases Negative for *YAP1* and *MAML2* Gene Abnormalities

HE #	HE Type	Age/Sex	Location
1	RHE	34/female	Elbow
2	RHE	14/male	Shoulder
3	RHE	18/male	Scalp
4	RHE	46/female	Knee
5	RHE	17/male	Forehead
6	RHE	46/female	Long finger
7	RHE	30/female	Thigh
8	RHE	55/male	Thigh
9	CHE	19/male	Hand
10	CHE	56/female	Forearm
11	CHE	24/female	Scalp
12	CHE	36/female	Scalp
13	CHE	35/male	Heel
14	CHE	12/male	Shoulder
15	CHE	68/female	Buttock
16	CHE	42/female	Finger

HE indicates hemangioendothelioma.

Although no significant microscopic differences were noted between the 2 CHE molecular groups, some of the fusion-negative cases showed more cellular solid growth and 1 showed a hemangioma-like pattern (Fig. 4).

Neuroendocrine CHE Variant is Associated With Aggressive Clinical Behavior and a Distinctive *PTBP1-MAML2* Fusion

A 37-year-old male presented with a pancreatic mass and multiple liver lesions. A liver biopsy was obtained which showed a predominantly retiform pattern of elongated vascular channels lined by enlarged, hobnailed endothelial cells (Fig. 3). A focal epithelioid component was also present. The lesional cells showed diffuse hyperchromasia, mild cytologic atypia, but no discernible increase in mitotic activity. Large areas of infarction were noted. By immunohistochemistry, the tumor cells were positive for CD31, ERG, and synaptophysin but negative for chromogranin. On the basis of the clinical presentation and morphologic appearance a diagnosis of low-grade angiosarcoma was suspected, and tissue was submitted for targeted RNA sequencing. The results showed the presence of a t(11;19) resulting in a *PTBP1-MAML2* fusion. The fusion reads showed the presence of 2 isoforms from alternative splicing, with *MAML2* being fused to either exons 2 or 10 of *PTBP1* (Fig. 2).

DISCUSSION

Both RHE and CHE are currently classified as locally aggressive, rarely metastasizing, vascular lesions in the latest WHO classification, occurring preferentially in the skin and soft tissue of the extremities, particularly in the lower limb.¹ RHE has a wider age range at diagnosis, often affecting children and young adults, with equal sex distribution, while CHE occurs chiefly in adults, with very rare pediatric or congenital cases, and a slight female predilection.^{1,5} Interestingly, in our cohort all *YAP1*-positive CHE occurred in female children in acral sites, while fusion-negative CHE cases occurred in adults of both sexes, and wide anatomic

distribution, including extremities and head and neck (Tables 1, 2). In contrast, RHE patients had a wide age range at diagnosis and anatomic distribution regardless of the *YAP1* gene rearrangement results.

RHE is characterized by distinctive arborizing blood vessels lined by endothelial cells with characteristic hobnail morphology, reminiscent of the normal rete testis. Remarkably, CHE contains at least 2 morphologically distinct vascular tumor elements, most often closely resembling RHE and EHE. Although CHE was previously defined as “an admixture of histologically benign, intermediate and malignant components,”⁶ the subsequent 2013 WHO classification revised its defining histologic features as a vascular neoplasm “containing an admixture of histologically distinct components,” thus removing the designation of various risks of malignancy.¹ This revised definition also reflects the typically favorable clinical course of patients with classic CHE, who, despite a high rate of local recurrence (~50%),⁷ likely a consequence of its infiltrative growth and incomplete excision, have a low risk of lymph node (6%) or distant (<1%) metastases.^{2,8} Of note the behavior of RHE mirrors that of CHE, showing a high local recurrence rate due to incomplete removal and a low rate of locoregional metastases.^{7,9,10}

A recent study of 11 CHE cases exhibiting neuroendocrine differentiation highlighted a preference for deep soft tissue location and a significantly more aggressive behavior compared with the typical forms of CHE, developing distant metastases in half of the patients with follow-up, including to bone, lung, liver, or brain.³ Although 3 of these cases were initially regarded as “angiosarcoma,”¹¹ the authors reclassified them as CHE in a subsequent study due to their “composite” constellation of histologic features, characterized by a distinctive admixture of retiform, nested, and solid/epithelioid areas, somewhat reminiscent of EHE. Thus, in their updated larger series including 11 patients, all cases showed morphologic features characteristic of CHE, including elongated, retiform vascular channels or “hemangioma-like” foci lined by hyperchromatic “hobnail” endothelial cells and solid growth of uniform epithelioid cells.³ Moreover, the tumors showed low mitotic activity, lacking necrosis or areas of conventional angiosarcoma. Interestingly, whole transcriptome analysis performed in 5 of the cases showed 1 case with *PTBP1-MAML2* and 1 case with *EPC1-PHC2* fusion transcripts; fusion transcripts were not identified in the remaining cases. Moreover, FISH testing for gene rearrangements in *MAML2* and *EPC1* genes were not identified in the negative cases. Of note, the authors conclude that this unusual hemangioendothelioma with neuroendocrine features likely represents a clinically aggressive variant of CHE, although they also raise the possibility of an unusual variant of RHE, or even an altogether distinct entity. Our single case of visceral neuroendocrine CHE included in this series is thus the second case reported with a *PTBP1-MAML2* fusion, with an identical transcript,³ suggesting a recurrent event which is distinct from the conventional CHE spectrum. As their second neuroendocrine CHE case showed an *EPC1-PHC2* fusion, we have tested our *YAP1* and

FIGURE 3. Morphologic features of *YAP1-MAML2* fusion-positive soft tissue CHE and *PTBP1-MAML2*-positive neuroendocrine CHE. A–C (case 6, 9/female; foot). Low power showing a predominant retiform component (A), with other areas showing solid sheets or cords of epithelioid cells, embedded in a diffusely fibrotic stroma (B). High power showing epithelioid cells and vacuolated cells as well as small vessels lined by plump epithelioid cells, obstructing the lumina (C). D–G (case 8, 7/female, middle finger). Low power showing a small retiform area with predominantly epithelioid cells arranged in cords and single cells in a sclerotic stroma (D). Numerous vacuolated cells can be seen (E). The lesion lacks a lobular growth pattern, with cords and single tumor cells encasing adnexal structures (F). The tumor is positive for D2-40 (G) and ERG (not shown). H and I (case 9, 37/male, liver biopsy). H, Neuroendocrine CHE with a predominant retiform architecture lined by uniform hobnailed endothelial cells. I, Tumor showed positivity for synaptophysin.

MAML2-negative cohort (Table 2) for *EPC1* gene rearrangements by FISH but none were found, once again suggesting that the genetic abnormalities seen in their cohort might be different from the regular CHE/RHE spectrum.

The diagnosis of RHE is often straightforward based on the characteristic elongated and narrow arborizing vascular channels, lined by monomorphic endothelial cells with prominent protuberant nuclei, with a typical tombstone or hobnail appearance. The cells have scant cytoplasm and lack nuclear pleomorphism or increased mitotic activity, often blending with the underlying fibrotic stroma. However, if the vascular channels are small or collapsed, the retiform architecture may be difficult to recognize. Focal solid areas composed of sheets of endothelial cells are often identified, which may suggest EHE or CHE. However, EHE is characterized

by cords of epithelioid cells with relatively abundant eosinophilic, glassy cytoplasm, and numerous vacuolated cells, which are embedded in a distinctive myxochondroid stroma, features not observed in RHE. Although rare intravascular papillae with hyaline collagenous cores may be occasionally seen as a focal finding in RHE, these are not as prominent as seen in papillary intralymphatic angioendothelioma (aka Dabska tumor).¹² RHE is the most common component of CHE, and therefore any additional architectural patterns seen adjacent to an RHE are diagnostic of CHE. However, the distinction between these 2 entities appears somewhat arbitrary, especially in CHE cases with a predominant RHE component, while the remaining patterns might be focal and characterized by nonspecific solid areas. Indeed, some discordance in assigning RHE versus CHE subtype was noted among the coauthors, suggesting the possibility of an over-

FIGURE 4. Histologic features of the molecular-negative subset of RHE and CHE. A and B, *YAP1*-negative RHE. A (14/male, shoulder), Low-power view showing dilated blood vessels within dermis lined by hobnail endothelial cells. B (55/male, thigh), Elongated, tubular vascular channels lined by cuboidal hyperchromatic endothelial cells, embedded in stroma with abundant lymphocytic infiltrate. C and D, CHE lacking *YAP1* or *MAML2* gene rearrangements. C (24/female, scalp), Predominant retiform areas with a focal epithelioid component arranged in single files. D (36/female, scalp), A variegated appearance showing solid, single cells as well as hemangioma-like areas.

lapping morphologic spectrum, centered on the retiform growth, with minor components of other patterns. However, the designation of RHE versus CHE in the current study was performed blinded to the molecular results.

CHE presents as a poorly circumscribed, infiltrative lesion that is typically centered in the dermis and subcutis, although occasional cases are deep-seated or involve viscera. It comprises a complex admixture of different vascular components that vary greatly in their relative proportions, which include RHE, EHE-like, hemangioma-like, angiosarcoma-like areas, etc. Not all cases contain every component. Vacuolated, pseudolipoblastic endothelial cells are frequently present. The angiosarcoma-like areas are usually characterized by a low-grade angiosarcomatous appearance, composed of complex dissecting vascular channels with subtle endothelial atypia and relatively few MFs. However, there is a single convincing reported case containing foci resembling high-grade epithelioid angiosarcoma.¹³ In contrast, conventional angiosarcoma is characterized by high nuclear grade, brisk

mitotic activity, and frequent necrosis. Neuroendocrine CHE is characterized by a distinctive admixture of RHE, EHE-like areas, and a component with a strikingly nested appearance, as well as by expression of neuroendocrine markers (most often synaptophysin).

Interestingly, both *YAP1* and *MAML2* related fusions have been reported previously in vascular lesions. First, *YAP1-TFE3* fusion, resulting in oncogenic TFE3 upregulation, represents the driver alteration of a small subset of EHE, showing distinctive morphologic features from the classic *WWTR1-CAMTA1* positive EHE, by displaying well-formed vascular channels lined by plump epithelioid cells with voluminous cytoplasm.^{14,15} Second, *WWTR1-MAML2* has been described recently in another subset of EHE, which has a predilection for the heart.¹⁶ *WWTR1* and its paralogue *YAP1* encode the proteins TAZ and YAP, respectively, which are downstream effectors of the Hippo tumor suppressor pathway and function as regulators of TEAD-dependent transcription.¹⁷ Other tumors harboring *YAP1* gene fusions include a subset of MUC4-negative sclerosing epithelioid

fibrosarcoma (*YAPI-KMT2A*)^{18,19}; recurrent *YAPI-MAML2* and *YAPI-NUTM1* fusions in poroma and porocarcinoma²⁰; and more recently *YAPI-MAML2* fusions have been reported in distinctive metaplastic thymomas.²¹ Moreover, *MAML2* gene fusions occur in most mucoepidermoid carcinomas (*MECT1-MAML2*, *CRTC1-MAML2*).²²

Our molecular findings suggest a close relationship between RHE and CHE, sharing in a similar proportion (one third of the cases) *YAPI* gene rearrangements, often with *YAPI-MAM2* gene fusions. We also report the second case of a neuroendocrine CHE with *PTBP1-MAML2* fusion, which appears to define a clinical subset with aggressive clinical behavior. Further NGS studies are needed to investigate the genetic signatures of the fusion-negative cases of RHE, CHE, and the aggressive, neuroendocrine subset of CHE.

ACKNOWLEDGMENTS

The authors thank and acknowledge the following referring pathologists who kindly provided case material: Dr Robert S. Katz, Morristown, NJ; Dr S. Sanders, Port Chester, NY; Dr Debra M. Jih, Horsham, PA; Dr Duane Barber, Calgary, AB; Dr Liz Roberts, Nelson, New Zealand; Dr Cher-Wei Liang, Taipei, Taiwan; Dr Igor Shendrik, Tulsa, OK; Dr Bostjan Luzar, Ljubljana, Slovenia; Dr Montserrat Giles, Middlesbrough, UK; Dr Chitra Pushpanathan, St. John's, NL; Dr Yushan Chiou, New York, NY; Dr Justin Hilson, Framingham, MA; Dr Elen Blochin, New York, NY; Dr Richard B. Hessler, Chattanooga, TN; Dr Muammar A. Arida, Greensboro, NC; Dr Sotirios Barbanis, Thessaloniki, Greece; Dr Michael Zhang, Newton, MA; Dr Ralph Winkler, Alpharetta, GA; Dr Stephen Lyle, Portsmouth, NH; Dr Joost van Gorp, Utrecht, The Netherlands; and Dr Giulio Rossi, Modena, Italy.

REFERENCES

- Rubin BP. Composite haemangioendothelioma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. *World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone*. Lyon, France: IARC Press; 2013:149–150.
- Nayler SJ, Rubin BP, Calonje E, et al. Composite hemangioendothelioma: a complex, low-grade vascular lesion mimicking angiosarcoma. *Am J Surg Pathol*. 2000;24:352–361.
- Perry KD, Al-Lbraheemi A, Rubin BP, et al. Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant. *Mod Pathol*. 2017;30:1589–1602.
- Kirchner M, Neumann O, Volckmar AL, et al. RNA-based detection of gene fusions in formalin-fixed and paraffin-embedded solid cancer samples. *Cancers (Basel)*. 2019;11:1309.
- Shang Leen SL, Fisher C, Thway K. Composite hemangioendothelioma: clinical and histologic features of an enigmatic entity. *Adv Anat Pathol*. 2015;22:254–259.
- Rubin BP. Composite haemangioendothelioma. In: Fletcher CD, Unni KK, Mertens F, eds. *World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone*, 3rd ed. Lyon, France: IARC Press; 2002:168–169.
- Calonje E, Fletcher CD, Wilson-Jones E, et al. Retiform hemangioendothelioma. A distinctive form of low-grade angiosarcoma delineated in a series of 15 cases. *Am J Surg Pathol*. 1994;18:115–125.
- Requena L, Luis Diaz J, Manzarbeitia F, et al. Cutaneous composite hemangioendothelioma with satellitosis and lymph node metastases. *J Cutan Pathol*. 2008;35:225–230.
- Bhutoria B, Konar A, Chakrabarti S, et al. Retiform hemangioendothelioma with lymph node metastasis: a rare entity. *Indian J Dermatol Venereol Leprol*. 2009;75:60–62.
- Mentzel T, Stengel B, Katenkamp D. Retiform hemangioendothelioma. Clinico-pathologic case report and discussion of the group of low malignancy vascular tumors. *Pathologe*. 1997;18:390–394.
- Tessier Cloutier B, Costa FD, Tazelaar HD, et al. Aberrant expression of neuroendocrine markers in angiosarcoma: a potential diagnostic pitfall. *Hum Pathol*. 2014;45:1618–1624.
- Albertini AF, Brousse N, Bodemer C, et al. Retiform hemangioendothelioma developed on the site of an earlier cystic lymphangioma in a six-year-old girl. *Am J Dermatopathol*. 2011;33:e84–e87.
- Leen SL, Clarke PM, Chapman J, et al. Composite hemangioendothelioma of the submandibular region. *Head Neck Pathol*. 2015;9:519–524.
- Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel *YAPI-TFE3* fusion defines a distinct subset of epithelioid hemangioendothelioma. *Genes Chromosomes Cancer*. 2013;52:775–784.
- Rosenbaum E, Jadeja B, Xu B, et al. Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets. *Mod Pathol*. 2020;33:591–602.
- Suurmeijer AJH, Dickson BC, Swanson D, et al. Variant *WWTR1* gene fusions in epithelioid hemangioendothelioma—A genetic subset associated with cardiac involvement. *Genes Chromosomes Cancer*. 2020;59:389–395.
- Tanas MR, Ma S, Jadaan FO, et al. Mechanism of action of a *WWTR1* (*TAZ*)-*CAMTA1* fusion oncoprotein. *Oncogene*. 2016;35:929–938.
- Kao YC, Lee JC, Zhang L, et al. Recurrent *YAPI* and *KMT2A* gene rearrangements in a subset of MUC4-negative sclerosing epithelioid fibrosarcoma. *Am J Surg Pathol*. 2020;44:368–377.
- Puls F, Agaimy A, Flucke U, et al. Recurrent fusions between *YAPI* and *KMT2A* in morphologically distinct neoplasms within the spectrum of low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma. *Am J Surg Pathol*. 2020;44:594–606.
- Sekine S, Kiyono T, Ryo E, et al. Recurrent *YAPI-MAML2* and *YAPI-NUTM1* fusions in poroma and porocarcinoma. *J Clin Invest*. 2019;130:3827–3832.
- Vivero M, Davineni P, Nardi V, et al. Metaplastic thymoma: a distinctive thymic neoplasm characterized by *YAPI-MAML2* gene fusions. *Mod Pathol*. 2020;33:560–565.
- Behboudi A, Enlund F, Winnes M, et al. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the *MECT1-MAML2* fusion oncogene. *Genes Chromosomes Cancer*. 2006;45:470–481.